Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 14;17(10):1367.
doi: 10.3390/ph17101367.

Cobaltabis(Dicarbollide) [ o-COSAN]- for Boron Neutron Capture Therapy of Head and Neck Cancer: Biodistribution and Irradiation Studies in an Experimental Oral Cancer Model

Affiliations

Cobaltabis(Dicarbollide) [ o-COSAN]- for Boron Neutron Capture Therapy of Head and Neck Cancer: Biodistribution and Irradiation Studies in an Experimental Oral Cancer Model

Mónica A Palmieri et al. Pharmaceuticals (Basel). .

Abstract

Background: Boron neutron capture therapy (BNCT) is a tumor-selective particle radiotherapy that combines preferential boron accumulation in tumors and neutron irradiation. Based on previous studies in tumor-bearing mice, this study evaluated the biodistribution of the sodium salt of cobaltabis(dicarbollide) (Na[3,3'-Co(C2B9H11)2], abbreviated as Na[o-COSAN]) in the hamster cheek pouch oral cancer model and the Na[o-COSAN]/BNCT therapeutic effect on tumors and induced radiotoxicity. The synthesis and comprehensive characterization of 10B-enriched trimethylammonium salt of nido-[7,8-C210B9H12]-o-carborane, along with the cesium and sodium salts of [o-10COSAN] cobaltabis(dicarbollide) are reported here for the first time.

Methods: Hamsters bearing tumors were injected with Na[o-COSAN] (7.5 mg B/kg) and euthanized at different time-points after injection (30 min, 2, 3, 5, and 18 h post-administration) to evaluate boron uptake in different tissues/organs. Based on these results, tumor-bearing animals were treated with Na[10B-o-COSAN]/BNCT (7.5 mg B/kg b.w., 3 h), prescribing 5 Gy total in absorbed dose to the precancerous tissue surrounding tumors, i.e., the dose-limiting tissue.

Results: Na[o-10COSAN] exhibited no toxicity. Although biodistribution studies employing Na[o-COSAN] have shown low absolute boron concentration in the tumor (approx. 11 ppm), Na[o-10COSAN]/BNCT induced a high and significant therapeutic effect on tumors versus the control group (cancerized, untreated animals). Moreover, only half of the animals exhibited severe mucositis in the precancerous dose-limiting tissue after BNCT, which resolved completely at 21 days after irradiation.

Conclusions: Na[o-10COSAN] would be potentially useful to treat head and neck cancer with BNCT.

Keywords: BNCT; Na[o-COSAN]; biodistribution studies; boron carrier; boron neutron capture therapy; hamster; head and neck cancer; metallacarborane.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Boron concentration values (ppm) for blood, tumor, and precancerous tissue at different time-points post Na[o-COSAN] injection: 30 min, 2 h, 3 h, 5 h, and 18 h.
Figure 2
Figure 2
Therapeutic effect of Na[o-10COSAN]/BNCT. Percentage of tumors with partial remission (PR) and complete remission (CR) considering tumor volume at the time of irradiation: small (<10 mm3), medium (≥10 <100 mm3), and large (≥100 mm3).

Similar articles

Cited by

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Gormley M., Creaney G., Schache A., Ingarfield K., Conway D.I. Reviewing the epidemiology of head and neck cancer: Definitions, trends and risk factors. Br. Dent. J. 2022;233:780–786. doi: 10.1038/s41415-022-5166-x. - DOI - PMC - PubMed
    1. Li Q., Tie Y., Alu A., Ma X., Shi H. Targeted therapy for head and neck cancer: Signaling pathways and clinical studies. Signal Transduct. Target. Ther. 2023;8:31. doi: 10.1038/s41392-022-01297-0. - DOI - PMC - PubMed
    1. Guidi A., Codecà C., Ferrari D. Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: A systematic review. Med. Oncol. 2018;35:37. doi: 10.1007/s12032-018-1096-5. - DOI - PubMed
    1. Kitamura N., Sento S., Yoshizawa Y., Sasabe E., Kudo Y., Yamamoto T. Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. Int. J. Mol. Sci. 2020;22:240. doi: 10.3390/ijms22010240. - DOI - PMC - PubMed

LinkOut - more resources